NR4A1 and breast cancer: Suppression of CETP led to a notable inhibition in the growth of triple-negative breast cancer, a breast cancer subtype devoid of hormone receptors, which are typically targeted by endocrine therapies, resulting in an 86% reduction in tumor size (37).